Profile of an Ideal Antianginal Agent Eliot J. LazarWilliam H. Frishman Section 1: The Profile of Epanolol: A New Antianginal Agent 29 November 2012 Pages: 1 - 8
Blood Pressure Control and Mortality — Is there a J-Shaped Curve? Hans Wedeldh Short Communication 29 November 2012 Pages: 9 - 9
Pharmacokinetics of Epanolol (ICI 141,292) in Healthy Young Volunteers and Comparative Data in Elderly Patients with Angina and Subjects with Renal or Hepatic Impairment I. D. Cockshott Section 1: The Profile of Epanolol: A New Antianginal Agent 29 November 2012 Pages: 10 - 17
Clinical Pharmacology of Epanolol Pharmacodynamic Aspects J. D. Harry Section 1: The Profile of Epanolol: A New Antianginal Agent 29 November 2012 Pages: 18 - 27
Epanolol Fawaz AkhrasGraham Jackson Section 1: The Profile of Epanolol: A New Antianginal Agent 29 November 2012 Pages: 28 - 34
Dose Finding in Angina — Results with Epanolol T. M. OmlandC. v. BrandisA. M. Abrahamsen Short Communication 29 November 2012 Pages: 35 - 38
Effect of Partial Agonist Activity on the Side Effects of β-Blockade in Patients with Chronic Stable Angina John ChambersMeiLin OngGraham Jackson Section 1: The Profile of Epanolol: A New Antianginal Agent 29 November 2012 Pages: 39 - 44
Results of a Long Term Multicentre Study in Sweden J. Boberg Short Communication 29 November 2012 Pages: 45 - 45
Discussion: Section 1 A. Reale Section 1: The Profile of Epanolol: A New Antianginal Agent 29 November 2012 Pages: 46 - 48
Chairman’s Comments: Section 1 A. Reale Section 1: The Profile of Epanolol: A New Antianginal Agent 29 November 2012 Pages: 49 - 49
Rationale and Statistical Methodology for the VISA Studies M. J. RatcliffeM. J. Godley Section 2: Epanolol in Stable Angina: The Visa Studies 29 November 2012 Pages: 50 - 54
Comparative Multicentre Study of the Tolerability and Efficacy of Epanolol versus Metoprolol in Patients with Stable Angina Pectoris N. Clark-Turner Section 2: Epanolol in Stable Angina: The Visa Studies 29 November 2012 Pages: 55 - 60
Comparative Multicentre Study of the Tolerability and Efficacy of Epanolol versus Nifedipine in Patients with Stable Angina Pectoris A. S. Readman Section 2: Epanolol in Stable Angina: The Visa Studies 29 November 2012 Pages: 61 - 65
Efficacy of Epanolol versus Metoprolol in Angina Pectoris Lars Rydénthe Swedish Multicenter Study Group Short Communication 29 November 2012 Pages: 66 - 66
Effects of Epanolol and Metoprolol on the Heart Measured by 24-Hour Holter Monitoring Adrie J. A. M. WithagenH. M. A. CorbeijA. Vermeulen Section 2: Epanolol in Stable Angina: The Visa Studies 29 November 2012 Pages: 67 - 69
Left Ventricular Function during Treatment with Either Metoprolol or Epanolol T. Evans Short Communication 29 November 2012 Pages: 70 - 70
The Effects of Epanolol on Quality of Life Sverker Jem Section 2: Epanolol in Stable Angina: The Visa Studies 29 November 2012 Pages: 71 - 74
Discussion: Section 2 A. J. CammL. Rydén Section 2: Epanolol in Stable Angina: The Visa Studies 29 November 2012 Pages: 75 - 79
Chairman’s Comments: Section 2 A. J. Camm Section 2: Epanolol in Stable Angina: The Visa Studies 29 November 2012 Pages: 80 - 80
An Overview of Clinical Trial Experience with Epanolol P. Blake Section 3: Patient Preference: The Ultimate Determinant 29 November 2012 Pages: 81 - 85
Panel Discussion A. J. Dunning Section 3: Patient Preference: The Ultimate Determinant 29 November 2012 Pages: 86 - 91